The IRDiRC Chrysalis Task Force: making rare disease research attractive to companies.

Katherine L Beaverson, Daria Julkowska,Mary Catherine V Letinturier,Annemieke Aartsma-Rus,Jennifer Austin,Juan Bueren, Simon Frost, Misako Hamamura, Jane Larkindale,Greg LaRosa, Rita Magenheim,Annamaria Merico,Anna Maria Gerdina Pasmooij, Vinciane Pirard,Nicholas Ekow Thomford,Michihiko Wada,Durhane Wong-Rieger,Adam L Hartman

Therapeutic advances in rare disease（2023）

引用 0|浏览11

暂无评分

摘要

The Chrysalis Task Force identified factors attributable to rare disease research and development that may be of interest to and actionable by funders, academic researchers, patients and their families, companies, regulators, and payers in the medium term to short term. By addressing the identified challenges, involved parties may seek solutions to significantly advance the research and development of treatments for rare diseases.

查看译文

关键词

irdirc chrysalis task force,rare disease research

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要